Regenerative Medical Technology (RMTG) files notice of late Q2 10-Q

Rhea-AI Filing Summary

Regenerative Medical Technology Group Inc. submitted a notice that its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 will be filed late. The company states it was unable, without unreasonable effort or expense, to timely compile all required financial statement information and related disclosures.

The company indicates that it expects to file the Form 10-Q within the five-day grace period provided by Rule 12b-25. The notification is signed by David Christensen, who serves as President, Chief Executive Officer, Chief Financial Officer, Secretary and Director.

Key Terms

Rule 12b-25, Quarterly Report on Form 10-Q, five-day grace period

3 terms

Rule 12b-25 regulatory

"the five-day grace period provided by Rule 12b-25"

Rule 12b-25 is an SEC filing provision that lets a company notify regulators and the public that it cannot file a required periodic report (like a quarterly or annual report) on time and explains the reason for the delay. For investors, the notice is a formal heads-up that financial information will arrive late—similar to a company calling to say it will be late turning in homework—so it signals increased uncertainty and may affect trading and risk assessments until the filing is available.

Quarterly Report on Form 10-Q regulatory

"its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026"

A quarterly report on Form 10-Q is a standardized financial filing public companies must submit to U.S. regulators every three months, summarizing recent financial results, cash flows, balance sheet changes, operations and material risks or legal developments. Investors treat it like a company report card that shows up-to-date facts rather than marketing copy, helping them track performance, spot trends, reassess risk and make buy or sell decisions.

five-day grace period regulatory

"expects to file the Quarterly Report on or before the five-day grace period"

FAQ

Why did Regenerative Medical Technology Group Inc. (RMTG) file an NT 10-Q?

Regenerative Medical Technology Group Inc. filed an NT 10-Q because it could not, without unreasonable effort or expense, complete the financial statements and disclosures for its Form 10-Q for the quarter ended June 30, 2026 in time for the normal deadline.

Which period does RMTG’s delayed Form 10-Q cover?

The delayed Form 10-Q for Regenerative Medical Technology Group Inc. covers the quarter ended June 30, 2026. The company indicates it needs additional time to compile financial statements and related disclosures for this specific reporting period.

When does RMTG expect to file the delayed Form 10-Q?

Regenerative Medical Technology Group Inc. states it expects to file the delayed Form 10-Q within the five-day grace period allowed under Rule 12b-25, following the original due date for the quarterly report.

What rule is RMTG relying on for its late 10-Q filing?

Regenerative Medical Technology Group Inc. is relying on Rule 12b-25, which provides a short grace period for late filings when a report cannot be completed on time without unreasonable effort or expense, provided certain conditions are met.

Who signed RMTG’s notice of late Form 10-Q filing?

The notice of late Form 10-Q filing for Regenerative Medical Technology Group Inc. was signed by David Christensen, who serves as President, Chief Executive Officer, Chief Financial Officer, Secretary and Director, acting as the principal executive, financial and accounting officer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/14/2026 - 10:54 AM Accepted by SEC EDGAR 08/14/2026 - 10:54 AM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SEC FILE NUMBER

000-56010

NOTIFICATION OF LATE FILING  

(Check One):	☐	Form 10-K	☐	Form 20-F	☐	Form 11-K	☒	Form 10-Q
	☐	Form 10-D	☐	Form N-SAR	☐	Form N-CSR

	For Period Ended: June 30, 2026
	☐	Transition Report on Form 10-K
	☐	Transition Report on Form 20-F
	☐	Transition Report on Form 11-K
	☐	Transition Report on Form 10-Q
	☐	Transition Report on Form N-SAR
	For the Transition Period Ended: ___________________

Read Instructions (on back page) Before Preparing Form. Please Print or Type.

NOTHING IN THIS FORM SHALL BE CONSTRUED TO IMPLY THAT THE COMMISSION HAS VERIFIED ANY INFORMATION CONTAINED HEREIN.

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

PART I - REGISTRANT INFORMATION

Full Name of Registrant:	Regenerative Medical Technology Group Inc.
Former Name if Applicable:	n/a
Address of Principal Executive Offices (Street and Number):	433 Plaza Real Suite 275 Boca Raton, Florida 33432

PART II - RULES 12b-25(b) AND (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed (Check box if appropriate)

	(a)	The reasons described in reasonable detail in Part III of this form could not be eliminated without  unreasonable effort or expense;
☒	(b)	The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
	(c)	The accountant’s statement or other exhibit required by Rule 12(b)-25(c) has been attached if applicable.

PART III - NARRATIVE

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

The Registrant has been unable, without unreasonable effort or expense, to timely compile all information for the financial statements and related disclosures required to be included in its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026. The Registrant expects to file the Quarterly Report on or before the five-day grace period provided by Rule 12b-25.

PART IV - OTHER INFORMATION

(1) Name and telephone number of person to contact in regard to this notification:

David Christensen		(800)		956-3935
Name		Area Code		Telephone Number

(2)	Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). ☒ Yes ☐ No
(3)	Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? ☐ Yes      ☒ No

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

2

Regenerative Medical Technology Group Inc.

(Name of Registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 14, 2026	By:	/s/ David Christensen
		Name: David Christensen Title: President, Chief Executive Officer, Chief Financial Officer, Secretary and Director (Principal Executive Officer) (Principal Financial Officer) (Principal Accounting Officer)

Instruction: The form may be signed by an executive officer of the registrant or by any other duly authorized representative. The name and title of the person signing the form shall be typed or printed beneath the signature. If the statement is signed on behalf of the registrant by an authorized representative (other than an executive officer), evidence of the representative’s authority to sign on behalf of the registrant shall be filed with the form.

ATTENTION

INTENTIONAL MISSTATEMENTS OR OMISSIONS OF FACT CONSTITUTE FEDERAL CRIMINAL VIOLATIONS (SEE 18 U.S.C. 1001).

3